INmune Bio reported a reduced net loss and significant progress across its CORDStrom™ and XPro™ platforms, with advancements in manufacturing, regulatory filings, and clinical trial data. The company also saw leadership changes and a substantial increase in cash and cash equivalents.
Net loss attributable to common stockholders decreased to approximately $6.5 million for Q3 2025, compared to approximately $12.1 million in Q3 2024.
positiveCORDStrom™ platform is on target for MAA submission mid-2026, followed by an anticipated BLA filing with the FDA.
positiveXPro1595 demonstrated consistent clinical benefits in early Alzheimer's patients, including slowed cognitive decline and reduced neuropsychiatric symptoms, with an excellent safety profile and no ARIA cases.
positiveCash and cash equivalents increased to approximately $27.7 million as of September 30, 2025, up from $20.9 million at the end of the prior period.
positiveAnnounced leadership changes including the appointment of David Moss as President & CEO and Cory Ellspermann as CFO.
neutralResearch and development expenses decreased to approximately $4.9 million in Q3 2025 from approximately $10.1 million in Q3 2024, indicating a potential slowdown in R&D activities.
attentionThe INKmune CARE-PC trial met its primary endpoint and 2 of 3 secondary endpoints, but the final secondary endpoint of 'reduction in tumor load' was not met, as patients enrolled had very high disease burden.
attentionNet loss for the nine months ended September 30, 2025 was $40.7 million, an increase from $32.9 million in the same period of 2024.
negativeTotal operating expenses for the nine months ended September 30, 2025 were $42.0 million, an increase from $33.2 million in the same period of 2024, driven by a $16.5 million impairment charge.
negativeMargin metrics will be available once backend extracts data from insights_json
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
Announced successful completion of first two commercial pilot-scale manufacturing runs of CORDStrom™.
CORDStrom™ is on target to file an MAA submission mid-2026, followed shortly thereafter by an anticipated BLA filing with the FDA.
XPro1595 demonstrated consistent clinical benefits in early Alzheimer's patients, including slowed cognitive decline and reduced neuropsychiatric symptoms.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.